EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies

Jeetendra Kumar Nag, Priyanga Appasamy, Hodaya Malka, Shoshana Sedley iD, Rachel Bar-Shavit iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jeetendra Kumar Nag und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem 91120, Israel. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells depend on specific oncogenic pathways or present a genetic alteration that leads to a particular disturbance. Still, personalized and targeted biological therapy remains challenging, with current efforts generally yielding disappointing results. Carefully assessing onco-target molecular pathways can, however, potently assist with such efforts for the selection of patient populations that would best respond to a given drug treatment. RNF43, an E3 ubiquitin ligase that negatively regulates Wnt/frizzled (FZD) receptors by their ubiquitination, internalization, and degradation, controls a key pathway in cancer. Recently, additional target proteins of RNF43 were described, including p85 of the PI3K/AKT/mTOR signaling pathway and protease-activated receptor 2 (PAR2), a G-protein-coupled receptor that potently induces β-catenin stabilization, independent of Wnts. RNF43 mutations with impaired E3 ligase activity were found in several types of cancers (e.g., gastrointestinal system tumors and endometrial and ovarian cancer), pointing to a high dependency on FZD receptors and possibly PAR2 and the PI3K/AKT/mTOR signaling pathway. The development of drugs toward these targets is essential for improved treatment of cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesNeoplasmsHumansSignal TransductionMolecular Targeted TherapyAnimalsTOR Serine-Threonine KinasesUbiquitinationPhosphatidylinositol 3-KinasesFrizzled ReceptorsReceptor, PAR-2MutationAntineoplastic Agents

Stichwörter der Autor:innen

G-protein-coupled receptors (GPCRs)RNF43/ZNRF3colon cancerprotease-activated receptors (PARs)proteasesβ-catenin stabilization

Substanzen

Ubiquitin-Protein LigasesRNF43 protein, humanTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesFrizzled ReceptorsReceptor, PAR-2Antineoplastic Agents

Autor:innen und Institutionen

  • Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem 91120, Israel.

ORCID-Profile: Shoshana Sedley, Rachel Bar-Shavit

Förderung

  • Israel Science Foundation

Zitieren

APA

Nag, J. K., Appasamy, P., Malka, H., Sedley, S., & Bar-Shavit, R. (2024). New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158083

Vancouver

Nag JK, Appasamy P, Malka H, Sedley S, Bar-Shavit R. New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158083

BibTeX
@article{Nag2024,
  author = {Nag, Jeetendra Kumar and Appasamy, Priyanga and Malka, Hodaya and Sedley, Shoshana and Bar-Shavit, Rachel},
  title = {New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158083}
}
Kostenlos starten →